Development and validation of a plasmalogen score as an independent modifiable marker of metabolic health : population based observational studies and a placebo-controlled cross-over study
Copyright © 2024 The Authors. Published by Elsevier B.V. All rights reserved..
BACKGROUND: Decreased levels of circulating ethanolamine plasmalogens [PE(P)], and a concurrent increase in phosphatidylethanolamine (PE) are consistently reported in various cardiometabolic conditions. Here we devised, a plasmalogen score (Pls Score) that mirrors a metabolic signal that encompasses the levels of PE(P) and PE and captures the natural variation in circulating plasmalogens and perturbations in their metabolism associated with disease, diet, and lifestyle.
METHODS: We utilised, plasma lipidomes from the Australian Obesity, Diabetes and Lifestyle study (AusDiab; n = 10,339, 55% women) a nationwide cohort, to devise the Pls Score and validated this in the Busselton Health Study (BHS; n = 4,492, 56% women, serum lipidome) and in a placebo-controlled crossover trial involving Shark Liver Oil (SLO) supplementation (n = 10, 100% men). We examined the association of the Pls Score with cardiometabolic risk factors, type 2 diabetes mellitus (T2DM), cardiovascular disease and all-cause mortality (over 17 years).
FINDINGS: In a model, adjusted for age, sex and BMI, individuals in the top quintile of the Pls Score (Q5) relative to Q1 had an OR of 0.31 (95% CI 0.21-0.43), 0.39 (95% CI 0.25-0.61) and 0.42 (95% CI 0.30-0.57) for prevalent T2DM, incident T2DM and prevalent cardiovascular disease respectively, and a 34% lower mortality risk (HR = 0.66; 95% CI 0.56-0.78). Significant associations between diet and lifestyle habits and Pls Score exist and these were validated through dietary supplementation of SLO that resulted in a marked change in the Pls Score.
INTERPRETATION: The Pls Score as a measure that captures the natural variation in circulating plasmalogens, was not only inversely related to cardiometabolic risk and all-cause mortality but also associate with diet and lifestyle. Our results support the potential utility of the Pls Score as a biomarker for metabolic health and its responsiveness to dietary interventions. Further research is warranted to explore the underlying mechanisms and optimise the practical implementation of the Pls Score in clinical and population settings.
FUNDING: National Health and Medical Research Council (NHMRC grant 233200), National Health and Medical Research Council of Australia (Project grant APP1101320), Health Promotion Foundation of Western Australia, and National Health and Medical Research Council of Australia Senior Research Fellowship (#1042095).
| Media Type: |
Electronic Article |
|---|
| Year of Publication: |
2024 |
|---|---|
| Publication: |
2024 |
| Contained In: |
To Main Record - volume:105 |
|---|---|
| Contained In: |
EBioMedicine - 105(2024) vom: 01. Juli, Seite 105187 |
| Language: |
English |
|---|
| Contributors: |
Beyene, Habtamu B [Author] |
|---|
| Links: |
|---|
| Keywords: |
Biomarkers |
|---|
| Notes: |
Date Completed 12.07.2024 Date Revised 31.08.2024 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1016/j.ebiom.2024.105187 |
|---|
| funding: |
|
|---|---|
| Supporting institution / Project title: |
|
| PPN (Catalogue-ID): |
NLM37349985X |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM37349985X | ||
| 003 | DE-627 | ||
| 005 | 20240901232600.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 240612s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.ebiom.2024.105187 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1519.xml |
| 035 | |a (DE-627)NLM37349985X | ||
| 035 | |a (NLM)38861870 | ||
| 035 | |a (PII)S2352-3964(24)00222-6 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Beyene, Habtamu B |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Development and validation of a plasmalogen score as an independent modifiable marker of metabolic health |b population based observational studies and a placebo-controlled cross-over study |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 12.07.2024 | ||
| 500 | |a Date Revised 31.08.2024 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright © 2024 The Authors. Published by Elsevier B.V. All rights reserved. | ||
| 520 | |a BACKGROUND: Decreased levels of circulating ethanolamine plasmalogens [PE(P)], and a concurrent increase in phosphatidylethanolamine (PE) are consistently reported in various cardiometabolic conditions. Here we devised, a plasmalogen score (Pls Score) that mirrors a metabolic signal that encompasses the levels of PE(P) and PE and captures the natural variation in circulating plasmalogens and perturbations in their metabolism associated with disease, diet, and lifestyle | ||
| 520 | |a METHODS: We utilised, plasma lipidomes from the Australian Obesity, Diabetes and Lifestyle study (AusDiab; n = 10,339, 55% women) a nationwide cohort, to devise the Pls Score and validated this in the Busselton Health Study (BHS; n = 4,492, 56% women, serum lipidome) and in a placebo-controlled crossover trial involving Shark Liver Oil (SLO) supplementation (n = 10, 100% men). We examined the association of the Pls Score with cardiometabolic risk factors, type 2 diabetes mellitus (T2DM), cardiovascular disease and all-cause mortality (over 17 years) | ||
| 520 | |a FINDINGS: In a model, adjusted for age, sex and BMI, individuals in the top quintile of the Pls Score (Q5) relative to Q1 had an OR of 0.31 (95% CI 0.21-0.43), 0.39 (95% CI 0.25-0.61) and 0.42 (95% CI 0.30-0.57) for prevalent T2DM, incident T2DM and prevalent cardiovascular disease respectively, and a 34% lower mortality risk (HR = 0.66; 95% CI 0.56-0.78). Significant associations between diet and lifestyle habits and Pls Score exist and these were validated through dietary supplementation of SLO that resulted in a marked change in the Pls Score | ||
| 520 | |a INTERPRETATION: The Pls Score as a measure that captures the natural variation in circulating plasmalogens, was not only inversely related to cardiometabolic risk and all-cause mortality but also associate with diet and lifestyle. Our results support the potential utility of the Pls Score as a biomarker for metabolic health and its responsiveness to dietary interventions. Further research is warranted to explore the underlying mechanisms and optimise the practical implementation of the Pls Score in clinical and population settings | ||
| 520 | |a FUNDING: National Health and Medical Research Council (NHMRC grant 233200), National Health and Medical Research Council of Australia (Project grant APP1101320), Health Promotion Foundation of Western Australia, and National Health and Medical Research Council of Australia Senior Research Fellowship (#1042095) | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Observational Study | |
| 650 | 4 | |a Diet | |
| 650 | 4 | |a Lifestyle intervention | |
| 650 | 4 | |a Metabolic health | |
| 650 | 4 | |a Pls Score | |
| 650 | 7 | |a Plasmalogens |2 NLM | |
| 650 | 7 | |a Biomarkers |2 NLM | |
| 650 | 7 | |a Phosphatidylethanolamines |2 NLM | |
| 700 | 1 | |a Huynh, Kevin |e verfasserin |4 aut | |
| 700 | 1 | |a Wang, Tingting |e verfasserin |4 aut | |
| 700 | 1 | |a Paul, Sudip |e verfasserin |4 aut | |
| 700 | 1 | |a Cinel, Michelle |e verfasserin |4 aut | |
| 700 | 1 | |a Mellett, Natalie A |e verfasserin |4 aut | |
| 700 | 1 | |a Olshansky, Gavriel |e verfasserin |4 aut | |
| 700 | 1 | |a Meikle, Thomas G |e verfasserin |4 aut | |
| 700 | 1 | |a Watts, Gerald F |e verfasserin |4 aut | |
| 700 | 1 | |a Hung, Joseph |e verfasserin |4 aut | |
| 700 | 1 | |a Hui, Jennie |e verfasserin |4 aut | |
| 700 | 1 | |a Beilby, John |e verfasserin |4 aut | |
| 700 | 1 | |a Blangero, John |e verfasserin |4 aut | |
| 700 | 1 | |a Moses, Eric K |e verfasserin |4 aut | |
| 700 | 1 | |a Shaw, Jonathan E |e verfasserin |4 aut | |
| 700 | 1 | |a Magliano, Dianna J |e verfasserin |4 aut | |
| 700 | 1 | |a Giles, Corey |e verfasserin |4 aut | |
| 700 | 1 | |a Meikle, Peter J |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t EBioMedicine |d 2014 |g 105(2024) vom: 01. Juli, Seite 105187 |w (DE-627)NLM244581355 |x 2352-3964 |7 nnns |
| 773 | 1 | 8 | |g volume:105 |g year:2024 |g day:01 |g month:07 |g pages:105187 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.ebiom.2024.105187 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a SYSFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 105 |j 2024 |b 01 |c 07 |h 105187 | ||